Answers are grounded in this paper and cite their sources.
During crizotinib treatment, ophthalmologic changes from baseline did not appear to be associated with patient-reported ocular TEAEs. Abnormal ophthalmologic findings occurred in the context of preexisting conditions for a number of patients. No ophthalmologic changes from baseline or ocular all-causality TEAEs required permanent treatment discontinuation.
No takes yet. Share an insight, caveat, or question.
Solomon et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: